[儿科. 在儿童. 川崎病] 川崎病] 川崎病] 川崎病]
Sabrina Bressieux-Degueldre1, Katerina Theodoropoulou2, Alain Lefèvre-Utile3
1Unité de cardiologie pédiatrique, Service de pédiatrie, Département femme-mère-enfant, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Revue medicale suisse
|January 16, 2026
概括
川崎病是幼儿急性血管炎,如果不治疗,可能导致冠状动脉问题. 更新的指导方针有助于早期诊断和治疗,改善受影响儿童的治疗结果.
科学领域:
- 儿科 儿科 儿科
- 类风湿病学 类风湿病学
- 心脏病学 心脏病学
背景情况:
- 川崎病是儿童获得心脏病的主要原因.
- 未经治疗的Kawasaki病具有显著的冠状动脉动脉瘤风险 (25%).
- 欧洲和北美近期的指南更新影响了诊断和治疗策略.
研究的目的:
- 总结了川崎病的最新诊断和管理指南.
- 突出法语瑞士Kawasaki疾病管理的关键实践.
- 讨论治疗耐火病例和预防冠状动脉并发症的进展.
主要方法:
- 审查目前欧洲和北美关于川崎病的指导方针.
- 基于临床症状和发烧持续时间的诊断标准的分析.
- 高风险冠状动脉标准的评估,以指导早期治疗决策.
主要成果:
- 诊断依赖于临床症状的组合 (皮肤,粘膜,淋巴体) 在发烧4天内发病的完整形式.
- 高风险冠状动脉标准对于迅速启动治疗至关重要.
- 免疫疗法和心脏护理方面的进步改善了耐药性疾病和冠状动脉并发症的预后.
结论:
- 以最新标准为指导的早期诊断和治疗对于预防川崎病冠状动脉异常至关重要.
- 目前的治疗策略,包括免疫调节和心脏疗法,为复杂病例提供了更好的结果.
- 遵守最新的指导方针和本地化实践是法国语瑞士最佳患者护理的关键.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Drug Metabolism
195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
500
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
500
Rheumatic Heart Disease I: Introduction
448
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
448
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246


